INTRODUCTION
The key reaction catalyzed by the ribosomal peptidyl transferase center (PTC), peptide bond formation, entails the transfer of the growing polypeptide from peptidyl-tRNA bound in the ribosomal P-site to the amino acid residue of aminoacyl-tRNA residing in the A-site. The ribosome accelerates this reaction $10 7 -fold (Sievers et al., 2004) by juxtaposing the reaction substrates for an efficient nucleophilic attack of the a-amino group of the aminoacyl residue onto the carbon atom of the ester bond linking the nascent peptide to the tRNA (Beringer et al., 2005; Weinger et al., 2004) . Amino acids delivered to the ribosomal A-site by aminoacyl-tRNAs differ significantly in their size, structure, and chemical properties. However, the catalytic center has evolved to allow for efficient transfer of the peptidyl moiety to any of the canonical amino acids placed in the A-site. The growing amino acid chain leaves the ribosome through the nascent peptide exit tunnel (NPET) that starts at the PTC and spans the body of the large ribosomal subunit. Through the decades of studies of mechanisms of protein synthesis, it has been largely assumed that the ribosome takes little notice of the nature of the polypeptide it makes. Only recently has it been realized that the ribosome can monitor the structure of the nascent peptide located in the exit tunnel (Tenson and Ehrenberg, 2002) . One of the best-recognized manifestations of this intriguing property of the ribosome is nascent peptidedependent translation arrest, which is at the heart of the regulatory mechanism that controls expression of several important bacterial and eukaryotic genes. In this mechanism, programmed ribosome stalling takes place at an upstream regulatory open reading frame (ORF) and leads to activation or repression of expression of the downstream gene(s) (Fang et al., 2004; Gong and Yanofsky, 2002; Nakatogawa and Ito, 2002) . Stalling ensues when the ribosome has polymerized a critical amino acid sequence encoded in the regulatory ORF. Specific interactions of the nascent peptide with sensory elements of the exit tunnel trigger structural rearrangements in the ribosome, which corrupt its functions and result in formation of a stalled ribosome complex (SRC) (Ito et al., 2010; Morris and Geballe, 2000; Ramu et al., 2009 ). The general principles of functional interactions between the ribosome and the nascent peptide are fundamental in their nature and may affect regulation of protein synthesis at different levels. However, molecular mechanisms that determine the ribosomal response to specific nascent peptide sequences are essentially unknown.
Clinically relevant erm genes in bacteria, which confer resistance to macrolide antibiotics, are regulated by drug-and nascent peptide-dependent ribosome stalling (Weisblum, 1995; Ramu et al., 2009) . Macrolides, e.g., erythromycin, bind in the ribosome exit tunnel in the vicinity of the PTC (Schlü nzen et al., 2001; Tu et al., 2005) . The erm-encoded enzyme methylates rRNA in the drug-binding site, reducing the affinity of the antibiotic to its target (Weisblum, 1995) . In the best-studied example of an inducible erm gene, antibiotic-dependent ribosome stalling at the ninth codon of the 19-codon regulatory ORF ermCL activates expression of the downstream resistance gene ermC (Gryczan et al., 1980; Horinouchi and Weisblum, 1980; Vazquez-Laslop et al., 2008) . The sequence of the four C-terminal amino acids (IFVI) of the ErmCL nascent peptide, which is essential for SRC formation, appears to be recognized by specific rRNA residues located in the PTC-proximal segment of the NPET (Vazquez-Laslop et al., 2008; Vá zquez-Laslop et al., 2010) .
One of the key unanswered questions about nascent peptidecontrolled translation arrest is why the ribosome stalls. In other words, what becomes ''broken'' in the ribosome in response to the presence of a specific nascent peptide in the exit tunnel? Several lines of evidence point to the importance of the PTC in programmed translation arrest (Gong and Yanofsky, 2002; Muto et al., 2006) . For example, the inefficient release by puromycin of the peptides from SRC suggested that stalling results from the impaired activity of the PTC (Gong and Yanofsky, 2002; Muto et al., 2006; Vazquez-Laslop et al., 2008) . Furthermore, spatial proximity of the NPET segments critical for stalling to the PTC makes the ribosome catalytic center the primary candidate for the target of the stalling response (Seidelt et al., 2009; Yap and Bernstein, 2009; Bhushan et al., 2010) . However, the functions of the PTC, which are highly sensitive to even minute alterations in its structure, can be disrupted in many different ways (Polacek and Mankin, 2005) . It remains unknown which aspect of the PTC function becomes corrupted in the SRC.
In this paper, we demonstrate that the presence of a drug and a specific nascent peptide in the ribosome exit tunnel dramatically alters the properties of the normally versatile PTC A-site to render it either selective or restrictive. The inability of the ribosome to efficiently incorporate specific amino acids in the growing polypeptide results in translation arrest. A conceptually similar mechanism may direct drug-independent ribosome stalling. These findings reveal the key role of the ribosomal A-site in SRC formation and clearly show that the functions of the PTC can be directly controlled by the nascent peptide located in the exit tunnel.
RESULTS

ErmAL1 Nascent Peptide Directs Programmed Translation Arrest
To understand the molecular principles of nascent peptidecontrolled translation arrest, we investigated SRC formation at the ermAL1 ORF. The ermA methyltransferase gene is preceded by two leader ORFs, ermAL1 and ermAL2 (Murphy, 1985) (Figure 1A) . The ermA transcript has the potential to fold into a secondary structure that sequesters the translation initiation region of ermAL2 and ermA (Murphy, 1985; Sandler and Weisblum, 1988) . By analogy with ermC, it was suggested that drug-dependent ribosome stalling at the ermAL1 ORF triggers translation of ermAL2 and that subsequent drug-dependent stalling at ermAL2 allows for activation of ermA expression (Murphy, 1985; Sandler and Weisblum, 1988) . The 19-amino acid ErmAL2 peptide is highly homologous to ErmCL and the ribosome translating ermAL2 stalls at the same ninth codon as in the previously investigated ermCL regulatory ORF (B) Primer extension inhibition analysis of the site of ribosome stalling at ermAL1. The ermAL1 ORF was translated in vitro in the absence (-) or presence (+) of erythromycin (Ery). A primer was annealed to the 3 0 end of mRNA and extended with reverse transcriptase (Vazquez-Laslop et al., 2008; Vá zquez-Laslop et al., 2010) . The same primer was used to generate sequencing lanes (U, C). The sequence of the ermAL1 gene and the encoded amino acids are shown to the left of the gel. Reverse transcriptase stops are indicated by arrowheads. The codon located in the P-site of the stalled ribosome is boxed. (C) The effect of mutations of codons 2-10 of ermAL1 on ribosome stalling. The amino acid changes associated with the codon mutations are indicated in the cartoon and over the corresponding lanes of the gel. The primer extension bands representing the ribosome stalled at the eighth ermAL1 codon are shown by arrowheads next to the gel. The lanes representing mutations at codons located in the P-and A-sites of the stalled ribosomes are boxed. In the cartoon, the star represents erythromycin bound in the tunnel. (Vazquez-Laslop et al., 2008) (Figure S1A, available online) . In contrast, the sequence of the 15 amino acid peptide encoded in ermAL1 is substantially different from both ErmCL and ErmAL2 (Figure 1A) , which makes it an attractive model for gaining new insights into the molecular mechanisms of drug-and nascent peptide-dependent ribosome stalling.
We investigated ribosome stalling at the ermAL1 ORF in vitro by using primer extension inhibition analysis (Hartz et al., 1988) . When the ermAL1 mRNA is translated in vitro in the presence of erythromycin, a strong band appears on the primer extension gel whose position shows that the ribosome comes to a standstill when the eighth (Val) codon of ermAL1 enters the ribosomal P-site ( Figure 1B ) (Vá zquez-Laslop et al., 2010) . To assess the role of the nascent peptide sequence in translation arrest, we mutated amino acid residues 2-8 of ErmAL1 one at a time to alanine (except for position 6, which is an alanine in the wild-type ermAL1 sequence and was mutated to a glycine). While changing codons 2-4 had no effect on SRC formation, mutations of codons Ile 5 , Ala 6 , Val 7 , or Val 8 abolished ribosome stalling ( Figure 1C ). To verify that ermAL1 mutations prevent translation arrest because of changes in the nascent peptide rather than in the mRNA structure, we introduced a total of nine synonymous mutations simultaneously at ermAL1 codons 2-7. Erythromycin-dependent stalling of the ribosome at the mutant mRNA was as prominent as with wild-type mRNA (Figure S1B) , indicating that it is the amino acid sequence of the ErmAL1 nascent peptide rather than the structure of its mRNA that guides SRC formation.
Stalled Ribosome Is Unable to Catalyze Peptide Bond Formation Translation arrest at the eighth codon of ermAL1 is compatible with two scenarios. The ribosome may stall because peptide bond formation is impaired; in this case an octapeptide encoded in the first eight codons of ermAL1 would be esterified to the P-site tRNA Val (Figure 2A ). Alternatively, if translation is arrested after the next peptide bond is formed, then a 9-amino acid peptide would be esterified to the A-site tRNA Glu , leaving a deacylated tRNA
Val in the P-site. To distinguish between these possibilities, we analyzed the nature of peptidyl-tRNA in the SRC by northern blotting. In the presence of erythromycin, tRNA 1 Val decoding the eighth ermAL1 codon GUA migrated more slowly in the gel, indicating its association with the nascent peptide (Figure 2A) . In contrast, the mobility of tRNA Glu corresponding to the ermAL1 ninth codon remained unchanged. This result shows that the ribosome arrested at the eighth codon of ermAL1 is unable to catalyze transfer of the 8 amino acid nascent peptide to the glutamyl moiety of Glu-tRNA Glu decoding the A-site codon. The Nature of the A-Site Amino Acid Is Critical for Stalling Previous studies of ribosome stalling at the ermCL regulatory ORF indicated that mutations of the codon located in the SRC A-site had little effect on stalling (Mayford and Weisblum, 1989; Vazquez-Laslop et al., 2008) . In striking contrast to those results, replacement of the Glu 9 codon of ermAL1 with an Ala (GCA) codon dramatically reduced the efficiency of SRC formation ( Figure 1C ). This indicates that the identity of the A-site codon and thus the nature of the aminoacyl-tRNA in the A-site are critical for drug-and nascent peptide-dependent translation arrest at ermAL1. We further verified this important conclusion by replacing the wild-type Glu 9 codon with codons specifying each of the other 18 conventional amino acids. Only a subset of the tested codons was found to be conducive to SRC formation ( Figure 2B ). Stalling was especially prominent with codons corresponding to charged amino acids (Glu, Asp, Lys, Arg, His). Codons specifying certain uncharged amino acids (Trp, Ile, Tyr) also strongly promoted translation arrest. In contrast, we found that in addition to the Ala codon, SRC formation was significantly reduced or even completely abolished when Phe, Met, or Cys codons replaced the Glu 9 codon of ermAL1 ( Figure 2B ). This unexpected observation that SRC formation at the ermAL1 ORF critically depends on the nature of the aminoacyl-tRNA specified by the A-site codon emphasized the importance of the ribosomal A-site in the mechanism of drugand nascent peptide-controlled translation arrest.
Mutations at the A-site codon result in binding of aminoacyltRNAs that differ from the wild-type Glu-tRNA Glu both in the structure of the tRNA body and in the nature of the acceptor amino acid substrate placed in the PTC. To discern which of these two features is central to the ribosome stalling response, we compared effects of pairs of tRNA isoacceptors differing in the structure of tRNA but delivering the same amino acid. The ninth codon of ermAL1 was replaced with pairs of synonymous codons decoded by glutamine, serine, leucine, and arginine tRNA isoacceptors ( Figure 2C ). Primer extension inhibition analysis showed that with each pair of synonymous codons, both isoacceptor aminoacyl-tRNAs were either equally conducive to SRC formation (pairs of tRNA Leu or tRNA Arg ) or similarly inefficient in promoting stalling (tRNA Gln or tRNA Ser pairs). This observation led us to conclude that the structure of tRNA itself had little influence upon translation arrest, which left the amino acid residue delivered to the PTC A-site as the primary determinant for discrimination.
The Ribosome Stalls Because Certain A-Site Amino Acids Serve as Poor Acceptors of the ErmAL1 Nascent Peptide
The northern blot analysis (Figure 2A) showed that the ribosome stalled at the eighth codon of ermAL1 is unable to transfer peptide from peptidyl-tRNA
Val to the A-site Glu-tRNA Glu , while the A-site codon mutations revealed that only a subset of aminoacyl-tRNAs are conducive to stalling (Figure 2B ). We therefore hypothesized that in the stalled ribosome, some stalling amino acids serve as particularly poor acceptors in the peptidyl transfer reaction, whereas other nonstalling amino acids are still able to function as fairly efficient substrates in the reaction of peptide bond formation. To directly test this hypothesis, we analyzed transfer of the ErmAL1 N-terminal octapeptide to model A-site substrates CCA-N-Lys or CCA-N-Ala in which the aminoacyltRNA 3 0 end analog CCA is linked via a stable amide bond to a stalling (Lys) or nonstalling (Ala) amino acid. Importantly, because binding of these substrates is codon independent, this experiment directly focuses on the role of the A-site amino acid in the formation of the stalled translation complex.
The ermAL1 mRNA, truncated after the eighth codon, was translated in vitro in the presence of [
35 S]-methionine and erythromycin. The SRC carrying radiolabeled peptidyl-tRNA was isolated by sucrose-gradient centrifugation and allowed to react with an excess (1 mM) of CCA-N-Lys or CCA-N-Ala ( Figure 3A ). We monitored progression of the reaction by quantifying the amount of unreacted peptidyl-tRNA resolved on a Tricine-SDS polyacrylamide gel (the reaction products CCA-N nonapeptides were too small to be resolved well enough for direct quantitation). The ErmAL1 nascent peptide in the SRC showed a strikingly different reactivity to the tested aminoacyl-tRNA analogs. The peptide was virtually unreactive with the substrate that contained the stalling amino acid (CCA-N-Lys) as could be judged from the essentially unchanged intensity of the peptidyl-tRNA band even after 30 min of incubation at 37 C. In contrast, the amount of SRC-associated peptidyl-tRNA rapidly decreased on incubation with CCA-N-Ala ( Figure 3A ), indicating that the ribosome could fairly efficiently catalyze transfer of the ErmAL1 nascent peptide to a nonstalling amino acid. While the tested aminoacyl-tRNA analogs showed a remarkably different reactivity with the peptidyl-tRNA in the SRC, both of them could be readily used as acceptors in the uninhibited reaction of peptide bond formation. When 70S initiation complex carrying fMettRNA in the P-site was reacted with these substrates, transfer of formyl-methionine to either CCA-N-Ala or CCA-N-Lys occurred very quickly: the band of fMet-tRNA completely disappeared after only 30 s of incubation-the shortest time point we could reliably acquire in our experimental setup ( Figure S2) . Thus, the results of the experiments with the model A-site substrates strongly supported our assertion that the presence of ErmAL1 nascent peptide and erythromycin in the NPET alters properties of the PTC A-site in such a way that peptide bond formation in SRC becomes particularly slow with certain amino acids.
We independently verified this conclusion by analyzing how the nature of the ninth amino acid in the ErmAL1 peptide (the A-site amino acid in the SRC) affects the frequency at which the ribosome can bypass the ermAL1 stalling site. In the presence of erythromycin, only a small fraction of the translating ribosomes could continue translation beyond the stalling site in the wild-type ermAL1: minute amounts of the full-length polypeptide were synthesized and a large amount of peptidyl-tRNA (probably corresponding to peptidyl-tRNA Val in the SRC) accumulated (Figure 3B) . When the ermAL1 ninth (Glu) codon was replaced with a codon of the nonstalling amino acid Phe, more than twice the amount of full-length polypeptide was produced with a concomitant decrease in accumulated peptidyl-tRNA. This observation was compatible with the notion that nascent peptide in the SRC could be transferred more efficiently to a nonstalling amino acid as compared with the wild-type (stalling) amino acid.
Altogether, these results illuminated an unexpected selectivity of the PTC A-site in the stalled ribosome, imposed by the presence of an antibiotic and a specific nascent peptide in the NPET. The versatile A-site, which efficiently operates with all types of natural aminoacyl-tRNAs in the normal ribosome, becomes highly selective to the nature of the acceptor substrate in the SRC. As a result, the PTC is unable to catalyze peptide bond formation with a range of natural amino acids.
The Properties of the PTC A-Site Depend on the Nascent Peptide Sequence The attributes of SRCs formed at the ermCL and ermAL1 regulatory ORFs are substantially different. While the nature of the A-site amino acid dramatically affects the efficiency of stalling at the ermAL1 ORF (Figure 2B ), ribosome stalling at the ermCL ORF is much less sensitive to the identity of the codon in the A-site of the stalled ribosome (Mayford and Weisblum, 1989; Vazquez-Laslop et al., 2008) (Figure S3 ). The ribosome that has polymerized the MGIFSIFVI sequence of the ErmCL peptide stalls irrespective of whether the A-site codon is Ser (wild-type) or is mutated to Glu (Figure 4 ). In contrast, the ribosome that has polymerized the eight N-terminal amino acids of the ErmAL1 peptide (MCTSIAVV) stalls when the ninth (A-site) codon is Glu (wild-type) but would not stall if it is mutated to Ser ( Figures 2B  and 4 ). Because in both cases ribosome stalling is controlled by the same drug (erythromycin) but different nascent peptides, it is most reasonable to think that the PTC A-site properties depend on the structure of the nascent peptide in the NPET. We then asked which of the critical amino acid residues of the stalling peptide in the tunnel define the properties of the A-site in the PTC?
Although the ErmCL (MGIFSIFVI) and ErmAL1 (MCTSIAVV) stalling nascent peptides are substantially different, the four C-terminal amino acids (IFVI in ErmCL and IAVV in ErmAL1) in both cases are critical for stalling (Figure 1C and Vazquez-Laslop et al., 2008) . When we transplanted the C-terminal sequence of the ErmAL1 stalling peptide to the ErmCL peptide rendering the hybrid sequence MGIFSIAVV, the stalled complex that formed at the ninth codon of the hybrid ORF acquired A-site selectivity characteristic of the ribosome stalled at ermAL1: SRC formed with Glu in the A-site but not with Ser (Figure 4) . Hence, determinants of the A-site properties reside within the four C-terminal amino acids of the stalling peptide. ErmCL wild-type (MGIFSIFVI), insensitive to the A-site codon, and the hybrid peptide (MGIFSIAVV), which shows a clear A-site codon selectivity, differ at only two residues: the ninth amino acid (Ile/ Val) that in the SRC esterifies the P-site tRNA and the seventh amino acid (Phe/Ala), at position À2 relative to the nascent peptide C terminus. Mutation of Ile 9 to Val in ErmCL had little effect on A-site selectivity. However, when Phe 7 of ErmCL was mutated to Ala, the SRC became sensitive to the nature of the A-site codon. If the same residue (Phe 7 ) was mutated to Gly, stalling was abolished altogether, irrespective of whether the ninth codon was Ser or Glu. Thus, within the context of the ErmCL nascent peptide, the identity of a single amino acid located in the NPET two residues away from the PTC defines the catalytic properties of the PTC active site.
DISCUSSION
Comparison of SRCs that form at regulatory ORFs ermAL1 and ermCL unmasked an important role of the PTC A-site in the mechanism of nascent peptide-controlled translation arrest. Our findings lead to a simple model that accommodates the known facts regarding drug-dependent translation arrest ( Figures 5A-5C ). Depending on the structure of the peptide in the NPET, the A-site can be in different states. During normal translation, the PTC A-site is in the versatile state when it can properly accommodate any of the natural amino acids delivered by aminoacyl-tRNA ( Figure 5A ). Peptide bond formation with any of the incoming amino acids is efficient. In the presence of an inducing antibiotic and a specific nascent peptide (e.g., ErmAL1), the A-site becomes selective ( Figure 5B ). Peptide bond formation with certain amino acids (red) becomes very slow; the corresponding A-site codons are conducive to SRC formation. Some peptide sequences (e.g., ErmCL) can impair the A-site even further, rendering it highly restrictive so that almost no amino acids can be comfortably accommodated (Figure 5C) ; essentially no natural amino acids can be efficiently used as peptide acceptor and the SRC is formed irrespective of the A-site codon. According to this view, the operational state of the PTC A-site can be directly influenced by the nascent peptide in the NPET and the properties of the A-site can be progressively altered depending on the nascent peptide sequence. Such a model is in excellent agreement with the results of computational simulations that suggest the PTC entry pathway during aminoacyl-tRNA accommodation can depend on the nature of the amino acid (Whitford et al., 2010) .
This model is not limited to drug-dependent translation arrest but can also account for key results of previous studies of drugindependent nascent peptide-controlled ribosome stalling. SRC formation at the natural or genetically modified secM regulatory ORF requires the presence of a proline codon in the A-site of the stalled ribosome (Muto et al., 2006; Yap and Bernstein, 2009) . Similarly, ribosome stalling at the sequences selected from a randomized peptide library requires the presence of a proline codon in the SRC A-site (Tanner et al., 2009 ). In these cases, the nascent peptides probably infringe on the A-site just enough to prevent use of the most structurally constrained amino acid, proline. In another extensively studied example of nascent peptide-dependent translation arrest, the ribosome stalls at the end of the tnaC regulatory cistron when either a stop codon or codons specifying Trp, Arg, Lys, or Ile are present in the A-site; however, stalling is diminished with certain other A-site codons (Cruz-Vera et al., 2009; Gong and Yanofsky, 2002) . In this case, the A-site appears to be more restrictive because it excludes a broader range of amino acids. It is noteworthy that the A-site codons that promote stalling at tnaC match the best-stalling codons we identified with ermAL1, suggesting that they are generally the easiest to discriminate against.
Except for proline, which is known to be a fairly inefficient nascent peptide acceptor because of its constrained structure and alkylation of the a-amino group (Pavlov et al., 2009) , the exact trend that distinguishes amino acids conducive to SRC formation at ermAL1 is unclear. Although the nature of the amino acid is known to influence aminoacyl-tRNA binding to the ribosome, indicating that each amino acid interacts with the PTC in a unique way (Fahlman and Uhlenbeck, 2004) , little structural information is available about the specifics of placement of different amino acids in the A-site. Only binding of Phe-tRNA or puromycin derivatives in the PTC A-site has been examined so far by high-resolution crystallographic analysis (Bashan The gels show the primer extension inhibition signal (bold arrowheads) representing SRC formation at different ORFs (erythromycin was present in all the samples). Bands corresponding to translation initiation sites at the erm ORFs are shown for reference and are indicated by thin arrows. The amino acid sequences corresponding to the ErmCL peptide are red and those representing the ErmAL1 peptide are blue. The Gly mutation at position 7 of ErmCL is shown in green, and the A-site amino acid is black. Amino acids located in the A-site of the PTC in the stalled ribosome are boxed with solid lines. The amino acid position À2 relative to the nascent peptide C terminus is boxed with a dashed line. et al., 2003; Nissen et al., 2000; Voorhees et al., 2009 ). In the analyzed complexes, the aromatic side chains of phenylalanine or puromycin are drawn into the hydrophobic crevice formed by the 23S rRNA residues A2451 and C2452 (Nissen et al., 2000; Voorhees et al., 2009) . However, precise molecular contacts of the amino acid side chains may vary depending on their chemical nature, even though the placement of the a-amino group that participates in the nucleophilic attack which drives the reaction of peptide bond formation should remain invariant. Thus, it is conceivable that even small alterations in the orientation of 23S nucleotides that constitute the PTC A-site may have a dramatic effect on the accurate placement of specific amino acids and their activity as peptidyl acceptors.
Our results show that the identity of the amino acid residue at position À2 relative to the C terminus of ErmAL1 and ErmCL nascent peptides is a key element that influences the properties of the A-site. When this position in the ErmCL nascent peptide in the tunnel is occupied by phenylalanine, the A-site becomes restrictive (the ribosome stalls with either Glu or Ser A-site codons). Replacement of Phe with Ala renders the A-site selective (stalling with Glu but not Ser A-site codons). Finally, when Phe is replaced with Gly, the A-site of the ribosome translating the ermCL ORF remains versatile (no stalling). Noteworthy is that the residue at the nascent peptide position À2 apparently also controls ribosome stalling at the secM ORF (Yap and Bernstein, 2009 ), reinforcing our previous notion that the mechanism of drug-dependent ribosome stalling at ermCL and ermAL1 shares many similarities with drug-independent translation arrest at the secM ORF (Vá zquez- Laslop et al., 2010) .
How is the information about the presence of a stalling nascent peptide sequence and, more specifically, the nature of the amino acid residue at position À2 communicated to the PTC A-site? In our previous work, we identified several important components of drug-dependent SRC formation. From the ribosome side, the identity of the 23S rRNA residues A2062 and A2503 located in the NPET were found to be critical for programmed translation arrest at ermCL and ermAL1 (Vazquez-Laslop et al., 2008; Vá zquez-Laslop et al., 2010) . From the side of an inducing macrolide antibiotic bound in the NPET, the presence of C3-cladinose is essential for stalling (Vazquez-Laslop et al., 2008) . If we are to assume that the nine-amino acid ErmCL nascent peptide can thread through the opening of the tunnel constricted by the bound antibiotic, then its Phe 7 (occupying position À2 of the nascent peptide) would be located only a short distance (2-4 Å ) from both the cladinose sugar of the inducing antibiotic and A2062 of the 23S rRNA ( Figure 5B ). Thus, as we proposed earlier (Vá zquez-Laslop et al., 2010) , the presence of cladinose-containing antibiotic ensures interaction of the nascent peptide (probably specifically the amino acid at position À2) with the highly flexible base of A2062, which serves as the peptide sensor. Reorientation of A2062 can alter the pose of A2503. Displacement of A2062 and A2503 can allosterically, In the presence of an inducing antibiotic (ery) and a specific nascent peptide (e.g., ErmAL1), the A-site becomes selective. Peptide bond formation with certain amino acids (red) becomes very slow; the corresponding A-site codons are conducive to SRC formation. (C) Certain peptide sequences (e.g., ErmCL) can render the A-site even more restrictive; the SRC is formed irrespective of the A-site codon. The ErmAL1 and ErmCL sequences essential for stalling are shown in cyan; the amino acid residue in position À2, which apparently controls the A-site properties, is blue. (D) A possible signal relay pathway communicating the information from the ribosomal exit tunnel to the PTC A-site. The eight-amino acid ErmAL1 nascent peptide, attached to the P-site tRNA, was modeled in the structure of Thermus thermophilus 70S ribosome (PDB accession number 2WDL; Voorhees et al., 2009 ). C-terminal amino acids critical for stalling are colored in cyan; the residue at position À2 is shown in blue. The 23S rRNA residues A2451 and C2452 forming the A-site crevice are orange. Erythromycin shape (ery) is shown as violet sticks and mesh with the cladinose residue highlighted in red. Mutations of residues A2062 and A2503 (purple) prevent stalling. Neighboring residues G2061 and U2504 (pale blue) may participate in communicating the stalling signal to the A-site crevice. The conformational flexibility of the rRNA residues putatively involved in relaying the stalling signal from the exit tunnel to the PTC is illustrated by their varying placements in different ribosomal complexes (Schmeing et al., 2005; Gü rel et al., 2009; Schuwirth et al., 2005; Jenner et al., 2005; Petry et al., 2005). via their immediate neighbors G2061 and U2504, affect the opening of the A2451/C2452 A-site crevice. This signal relay pathway is supported by rigid theory analysis of the statics of the tunnel (Fulle and Gohlke, 2009 ) and SRC structural studies (Seidelt et al., 2009) . It is noteworthy that the extent of the A-site impairment in the SRC formed at the ermCL ORF conspicuously correlates with the size of the amino acid in position À2 of the nascent peptide: the bulkiest Phe renders the A-site restrictive, the intermediate-sized Ala renders the A-site selective, and the smallest Gly leaves the A-site versatile. In terms of our model, a larger residue at position À2 of the nascent peptide would cause a stronger displacement of the tunnel sensors resulting in a more pronounced A-site distortion. The size of amino acid in position À2 of the peptide is probably not the only characteristic that defines its role in stalling. Hydrophobicity, charge, and other chemical properties may influence its interactions with the NPET sensors.
The A-site impairment is probably only one component of the stalling mechanism, even though it is critical. The identity of the P-site amino acid also has a direct effect on SRC formation (Gong and Yanofsky, 2002; Muto et al., 2006; Tanner et al., 2009; Vazquez-Laslop et al., 2008) . It is generally possible that the selectivity of the A-site in SRC revealed by our data is induced via improper placement of peptidyl-tRNA in the ribosomal P-site, which can be affected by specific interactions of the nascent peptide with the tunnel walls and the presence of additional ligands in the tunnel or PTC. Furthermore, different stalling peptides may affect the A-site properties via different relay pathways (Seidelt et al., 2009; Vá zquez-Laslop et al., 2010) . Nevertheless, the importance of the nature of the A-site codon for ribosome stalling at a variety of regulatory ORFs (Ramu and Mankin, unpublished data) shows that nascent peptide-induced selectivity of the PTC A-site is a common theme in the mechanism of programmed translation arrest.
EXPERIMENTAL PROCEDURES Primer Extension Inhibition Assay
Linear DNA templates for in vitro translation were generated by PCR as described (Vá zquez-Laslop et al., 2010) . Primers are listed in Table S1 . DNA templates were expressed in a cell-free transcription-translation system ) (PURExpress kit, New England BioLabs) and primer extension inhibition analysis was performed as described previously (Vazquez-Laslop et al., 2008) .
Identification of Peptidyl-tRNA in the ermAL1 SRC by Northern Hybridization The ermAL1 ORF DNA equipped with the T7 promoter was chemically synthesized (BioBasics, Inc.) and introduced into BamHI-ApaI sites of the pUC57 vector to generate plasmid pErmAL. The plasmid was used to direct cell-free transcription-translation reactions (Promega T7 S30 system for circular DNA). Ten microliter reactions, assembled according to the manufacturer's protocol and supplemented with 0.8 mg of plasmid, were incubated at 37 C for 30 min and then on ice for 10 min. When needed, the reactions were supplemented with erythromycin (final concentration: 50 mM). SRC was isolated by filtering the reactions through a Microcon YM-100 column (molecular weight cutoff of 100 kDa). The retained material was diluted to 200 ml with 0.3 M sodium acetate, pH 4, and total RNA was extracted with acidic phenol/chloroform followed by precipitation with ethanol. RNA-associated material was subjected to denaturing gel electrophoresis under acidic conditions (Varshney et al., 1991) , transferred to a Hybond N+ nylon membrane (GE Healthcare), and probed with radiolabeled DNA oligos complementary to tRNA Val (UAC) or tRNA Glu (UUC) ( Table S1 in Supplemental Information). After hybridization, membranes were air dried and exposed to phosphorimager screens.
Isolation of ermAL 8 -SRC and In Vitro Peptidyl Transfer Reaction
Commercially synthesized (Thermo Fisher) transcript encoding ermAL truncated at the eighth codon (ATAAGGAGGAAAAAATATGTGCACCAGTATCGC AGTAGTA) was used to direct the S30 cell-free translation reaction (Promega E. coli S30 Extract System for Linear Templates). The 50 ml reaction contained 8 mM transcript, 50 mM erythromycin, 0.4 mCi/mL [ 35 S]-methionine, and 2.4 U/mL RiboLock RNase Inhibitor (Fermentas) and was carried out for 30 min at 37
C. An equal volume of gradient buffer (20 mM Tris-HCl, pH 7.5, 15 mM MgCl 2 , 10 mM NH 4 Cl, and 2 mM b-mercaptoethanol) containing 50 mM erythromycin was added to the sample prior to loading onto a 5%-30% sucrose gradient prepared in the same buffer supplemented with 50 mM erythromycin. Gradients were centrifuged in a SW41 rotor at 39,000 rpm for 3 hr at 4 C. Fractions containing 70S complex were pooled, concentrated (Vivaspin100, Sartorious), and stored at À20
C. Sucrose-gradient-purified SRCs (0.6 mM) were combined with CCA-N-Lys or CCA-N-Ala (1 mM) in Pure System Buffer ) containing 50 mM erythromycin in a final volume of 22 mL. Reactions were incubated at 37 C and aliquots were removed at 1, 2.5, 5, 15, and 30 min. Reactions were stopped by precipitation with cold acetone and products were analyzed in a 16% BisTris polyacrylamide gel as described in http://openwetware.org/wiki/ Sauer:bis-Tris_SDS-PAGE,_the_very_best based on US patent 6,162,338.
Analysis of Translation Products of ermAL Wild-Type and Mutant ORFs
To enable visualization of the ErmAL leader peptide by gel electrophoresis, we extended the ermAL1 ORF in permAL to 72 codons by introducing a frameshift mutation (QuikChange II XL Site-Directed Mutagenesis Kit, Stratagene) at codon 12 of ermAL by using primers ermAL-shift1 and ermAL-shift2 (Table  S1 ) and generating a plasmid ermAL-FS. Subsequently, the ermAL1 ninth codon (GAA)-encoding glutamic acid was changed to TTC (phenylalanine) by using primer permAL.FS-F, producing plasmid permAL-FS-E9F.
Extended ermAL1 genes were expressed in a cell-free transcription-translation system (Promega T7 S30 system for circular DNA). Reactions (6.4 mL) contained 0.5 mg of plasmid DNA and 0.75 mCi of [ 35 S]-methionine (1175 Ci/ mmol; when needed, they were supplemented with erythromycin, 50 mM final concentrations). The reactions were incubated at 37 C for 15 min. After precipitation with acetone, translation products were fractionated by Tricine-SDS gel electrophoresis (Schä gger and von Jagow, 1987 The synthesis started from commercially available compound 1 from Chemgene.Oxidation of the 3 -hydroxyl group of 1 with CrO 3 /Py/Ac 2 O in CH 2 Cl 2 afforded the corresponding ketone intermediate, which was reduced by NaBH 3 CN stereoselectively to generate the 3 --isomer 2. Intermediate 2 was converted to the triflate 3 by treatment with trifluoromethanesulfonyl chloride in the presence of DMAP. The SN 2 replacement reaction of 3 with sodium azide in DMF at room temperature gave 3 --azido nucleoside 4. The azide 4 was converted into amine 5 by treatment 4 with triphenyl phosphine and then coupled amine 5 with protected amino acids to give 6a or 6b. After removal of 5 -DMTr by trichloracetic acid, intermediate 7a or 7b were obtained, respectively. Using compound 7a as a model compound, we optimized the conditions to remove the protecting groups. Fmoc and benzoyl groups were removed by treatment with 3:1 NH 4 OH:EtOH at 55 C for 2 h. The 1 H NMR indicated that both the benzoyl group and the Fmoc group were removed completely.
Cytidine 3 -H-phosphonate 12 was then coupled with 7a in the presence of 2,6-lutidine with trimethylacetyl chloride as coupling reagent and the reaction was monitored by TLC. About 10 equivalents of trimethylacetyl chloride was required to push the reaction into near completion. TCA treatment removed the 5 -DMTr group of 8a, and the coupling product 8a was purified by column chromatography. The 31 P NMR spectrum of 8a shows two peaks at 10.2 and 9.6 ppm---the typical region of H-phosphonate. Compound 8b was prepared similarly. The 5 -DMTr group of 8a and 8b was then removed by treatment of TCA to give 9a and 9b, respectively. The 5 -hydorxyl group of 9a or 9b was coupled with 12 again under the same coupling condition to give 10a and 10b, respectively. Without purifying 10a and 10b, the crude 10a or 10b was treated with iodine followed by removal of 5 -DMTr group by treatment of TCA. The resulting intermediates were fully deprotected by ammonia treatment followed by fluoride treatment to give the final products 11a and 11b, which were further purified by HPLC. The MALDI-MS confirmed their structures. With 11a, [MH] + =948, with 11b, [MH] + =1005. The p-ACCA-N-Lys or p-ACCA-N-Ala conjugates that were also tested in the peptidyl transfer experiments but are not reported in the paper were prepared as described by Moroder et al., (2009) . 
GGTTATAATGAATTTTGCTTATTAACGATAGAATTCTATCACTTAATGAAC TGTTTCGATTACAGCAATACTAAAAATGCC
Oligonucleotides used for generating ermAL2 template ermAL2-F TAATACGACTCACTATAGGGCTTAAGTATAAGGAGGAAAAAATATGGGT ACTTTTTCTATATTTGTTATTAATAAAGTTCG ermAL2-R GGTTATAATGAATTTTGCTTATTAACGATAGAATTCTATCACTTAATTTTG ATTTGGTTGATAACGAACTTTATTAATAACAAA Oligonucleotide probes for Northern hybridization tRNA Val (UAC) TGGGTGATGACGGGATCGAACCGCCGACCCCCTCCTTGTAAGGGAGGTGC TCTCCCAGCTGAGCTAATCACCC tRNA Glu (UUC) CGTCCCCTAGGGGATTCGAACCCCTGTTACCGCCGTGAAAGGGCGGTGTC CTGGGCCTCTAGACGAAGGGGAC a) For generating temples for cell-free transcription-translation, each primer pair was used in combination with T7fwd and NV1. b) For ermAL1 codon 9 mutations, the forward primer was ermAfwd in all cases. c) The ermCL ORF was truncated to 13 codons.
